Gilead Sciences Inc. has reached settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. to resolve ongoing patent litigation concerning generic versions of Biktarvy, the company's HIV treatment. As part of the agreements, which remain subject to standard acceleration provisions, generic versions of Biktarvy will not be introduced in the United States before April 1, 2036. The settlements follow legal challenges from the generic manufacturers, who had sought FDA approval to market their own versions of the drug.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000882095-25-000041), on October 06, 2025, and is solely responsible for the information contained therein.